



BAL PHARMA LIMITED
 Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2012

(Rs.in Lakhs)

Sr. No:	Particulars	Quarter Ended 30.06.2012	Quarter ended 31.03.2012	Quarter ended 30.06.2011	Year ended 31.03.2012
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Net Sales/Income from operations	2,952.30	3,976.63	2,798.22	13,648.98
	Other Operating Income	46.61	-	34.88	319.68
	Net Income from Sales/Services	2,998.90	3,976.63	2,833.10	13,968.66
2	Expenditure				
	a) Increase/decrease in stock in trade and WIP	(254.20)	311.00	(82.87)	120.28
	b) Consumption of Raw Materials/ Packing Material	1,656.43	1,880.32	1,507.65	7,184.63
	c) Purchase of Stock in Trade	55.92	158.88	86.48	375.24
	d) Employee Cost	585.56	310.30	501.98	2,115.41
	e) Depreciation and amortisation expenses	95.65	138.22	82.60	413.08
	f) Other Expenditure	655.64	862.23	546.98	2,692.40
	g. Total	2,795.06	3,660.95	2,642.83	12,901.05
3	Profit from Operations before other Income, interest and Exceptional items(1-2)	203.85	315.68	190.27	1,067.61
4	Other Non-operating Income	10.36	34.75	10.70	107.81
5	Profit before Interest and Exceptional items (3+4)	214.21	350.43	200.97	1,175.42
6	Interest	188.34	155.81	173.33	729.91
7	Profit after Interest but before Exceptional items	25.87	194.62	27.64	445.51
8	Exceptional items	-	-	-	-
9	Profit/ Loss from ordinary activities Before Tax (7-8)	25.87	194.62	27.64	445.51
10	Tax expenses	6.28	31.38	10.00	69.82
11	Net Profit / Loss from ordinary Activities after Tax	19.60	163.24	17.64	375.69
12	Extra ordinary items	-	-	-	-
13	Net Profit / Loss for the period	19.60	163.24	17.64	375.69
14	Paid-up Equity Share capital(face value of Rs 10 each)	1,057.36	1,057.36	1,048.32	1,057.36
15	Reserves excluding Revaluation Reserves as per balance sheet	-	-	-	2,948.22
16	EPS (in Rs.)				
	a) Basic	0.19	1.54	0.17	3.57
	b) Diluted	0.19	1.54	0.17	3.57
17	Public shareholding				
	- Number of Shares	5,142,086	5,132,086	5,061,586	5,132,086
	- Percentage of shareholding	48.63%	48.53%	48.28	48.53%
18	Promoters & Promoter group Shareholding				
	a) Pledged / Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of shareholding	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	5,431,538	5,441,538	5,421,638	5,441,538
	- Percentage of shareholding	51.37%	51.46%	51.72	51.46%

Notes:

- The above Un-Audited financial results as reviewed by the Audit Committee were approved by the Board of Directors at their meeting held on 10.08.2012.
- Statutory Auditors of the Company has conducted a limited review on the Un-Audited financial results for the quarter ended 30.06.2012.
- Your Company has received an outstanding export excellence award from the Sri Lankan Government for its export of drugs and medical equipments to the said Country.
- Investor grievances: Outstanding at the beginning of the quarter : Nil , received during the quarter:5,resolved during the quarter 5, pending at the end of the quarter: Nil.
- Previous year figures were regrouped / rearranged wherever required.
- As the Company deals with a single product i.e Pharmaceuticals, segment wise figures are not furnished.

Bangalore
10th August 2012

By order of the Board of Directors
For Bal Pharma limited

Shailesh Siroya
Managing Director